PT-141 (Bremelanotide)
Learn about bremelanotide’s specific approved use and why desire, arousal, pain and performance need different conversations.
Have questions? Start with a free consultation.
No deposit. Our Gilbert team will contact you within one business day.
Understand the topic before choosing a treatment
PT-141 is another name for bremelanotide, the active ingredient in VYLEESI. Its approved use is acquired, generalized hypoactive sexual desire disorder in premenopausal women who meet the prescribing criteria.
Sexual concerns can involve desire, arousal, discomfort, erections, medications or relationship context. A private conversation can clarify which concern is affecting you without assuming that everyone needs the same treatment.
This is an educational guide. It does not establish product availability or that this option is suitable for you.
How it works—and what that tells us
Bremelanotide acts at melanocortin receptors. Its precise mechanism for improving desire in the approved population is not fully understood. It should not be described as interchangeable with medicines that primarily address erectile blood flow.
A mechanism explains how something may act.
Clinical studies test benefits and harms in specific people.
Your goals and health history shape the next step.
What the evidence shows
Approved product with a defined indication
VYLEESI trials and labeling address a specific form of low desire in premenopausal women. The approval does not extend to men, postmenopausal women or general sexual-performance enhancement.
What it does not establish
- The approved product’s evidence does not automatically validate a compounded version or a combination blend.
- Low desire is not diagnosed from a questionnaire score alone; contributing factors and distress matter.
Safety questions worth discussing
- VYLEESI is contraindicated with uncontrolled high blood pressure or known cardiovascular disease.
- Nausea, transient blood-pressure changes and pigmentation changes are important labeled risks; a clinician should review medicines and pregnancy plans.
Bring your goals to the conversation
You can start with what you want to understand or improve. A consultation can help you assess the research and discuss other approaches; it does not commit you to a particular treatment.
- Is my main concern desire, arousal, pain or another change?
- Could a medicine or health condition be contributing?
- What options fit my situation and evidence-based treatment goals?
Common questions about PT-141 (Bremelanotide)
Is PT-141 approved for everyone with low libido?
No. The approval belongs to VYLEESI for a defined condition and population. It is not a universal libido or performance treatment.
Is this the same as Viagra or Cialis?
No. The products address different pathways and have different indications and safety considerations.
Do I need to describe intimate details in the request form?
No. Use the request to arrange a conversation. Discuss sensitive concerns privately with the clinical team.
Sources and further reading
- VYLEESI (bremelanotide) prescribing information
DailyMed / National Library of Medicine · Current product labeling - Understanding the risks of compounded drugs
U.S. Food and Drug Administration · Current guidance
The cited sources describe particular products, study populations or research questions. They are not endorsements of a LifeSpann treatment. Meet our team.
Start with your goals. The consultation is free.
Free consultation · No deposit
Talk through what you want to achieve, the evidence, and the options worth considering. You do not need to choose a peptide or commit to treatment.
Our front desk will contact you within one business day to answer questions and schedule your consultation.
Prefer to call? (480) 351-7151